FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/14/2024
Back to search
Official data from USPTO
DRUGOME
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
12/14/2024
Trademark type
Combined
Nice classes
9, 35, 36, 42
Filing date
08/19/2022
Registration date
06/11/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/11/2024
Last transaction
06/11/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
JP
Examiner
WUDARSKY, MINDY CHEK
Law office
M80
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of adjoining incomplete polygons appearing as stylized molecules next to the word "DRUGOME" in stylized lettering.
Holders and representatives
Holders
Sumitomo Pharma Co., Ltd.
Representatives
B. Brett Heavner Finnegan, Henderson, Farabow, Garrett &
Technical classification
Nice Classes
Class 9Class 35Class 36Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 9
Calculating machinesdata processing equipmentcomputers; downloadable computer software for data aggregation automationdatabase creationdata analysisdata reporting and data visualization; downloadable computer software for providinganalyzing and generating reports; downloadable computer software for data processing; electronic apparatuselectronic equipmentdownloadable computer software and programs for the capturecollectionconversionanalysiscommunicationprocessingreceivingrecordingstorage and transmission of dataimages and information; electronic apparatuselectronic equipmentdownloadable computer software and programs for the conversionanalysisprocessingstorage and transmission of artificial intelligence; downloadable computer software for database integration; downloadable computer software for creating searchable databases of information and data; downloadable software for analytics in the fields of healthcarepharmaceuticalsbiomedicinepharmaceutical and biomedical research and developmentfor clinical trial and post-market trial data; downloadable computer software featuring electronic computer databases of pharmaceuticalsbiomedical research in support of data analysis and for clinical trial and post-market trial data; downloadable computer search engine software for compilingaccessing and providing updated scientificmedicalpharmaceutical and clinical informationnews information of general interest
Class 35
Advertising services; business management; business administration; providing office functions; business research services; business information services; market research; provision of market research information; data processing services; analysis of business data; statistical analysis and reporting services using artificial intelligence and machine learning for business purposes in the pharmaceutical and biomedical fields; business analysis and statistical analysis of healthcare datapharmaceuticalsbiomedical researchfor clinical trial and post-market dataall the foregoing for business purposes; systematization of data in computer databases; compilation of data for business analysis purposescompilation of information into computer databases for business data analysis purposes in the fields of healthcarepharmaceuticalsbiomedicinepharmaceutical and biomedical research and developmentclinical trials and post-market data; professional business data analysis and consultancy and statistical analysis for business purposes in the fields of healthcarepharmaceuticalsbiomedicineclinical trialsepidemiological researchpharmacoepidemiological researchpost-market trials and research evaluating epidemiological outcomes
Class 36
Financial analysis; financial consulting; financial valuations and forecasting; financial analysis of statistics and data; financial analysis of investments in pharmaceutical and biomedical research and developmentclinical and post-market trials; financial evaluationtrackinganalysisforecastingconsultancyadvisory and research services relating to healthcarepharmaceuticalsbiomedicinepharmaceutical and biomedical research and developmentclinical and post-market trials
Class 42
Scientific and technological servicesdata aggregation automationdatabase creationdata analysisdata reporting and data visualization in the field of healthcarepharmaceuticalsbiomedical researchfor clinical trial and post-marketing and research and design relating thereto; analysis of technical data by computersdata automation and collection service using proprietary software to evaluateanalyze and collect dataproviding use of online non-downloadable software for analyzing data; pharmaceuticalbiomedicalbiological therapeutic research services; research in the field of pharmaceutical and biologic therapeutic preparations; pharmaceutical and biopharmaceutical research and development; providing scientific research information in the field of pharmaceuticalsbiomedicineclinical trials and post-market trials; cloud computing featuring software for use in data aggregation automationdatabase creationdata analysisdata reporting and data visualization; providing temporary use of online non-downloadable computer software featuring electronic computer databases of pharmaceuticalsbiomedicinepharmaceutical and biopharmaceutical research and developmentmedical informationclinical trial and post-market trial data for data analysisdata reporting and data visualization; providing temporary use of online non-downloadable computer software for research in the field of pharmaceuticals and biopharmaceuticals; providing temporary use of online non-downloadable computer software for compilingaccessingcontrollingmanaging and providing updated scientificpharmaceuticalmedical and clinical informationnews information of general interest; providing temporary use of non-downloadable software applications accessible via a web site for data analyticsfinancial analytics and risk management for use in the fields of pharmaceutical and biomedical research and developmentclinical trialsthe provision of medical and healthcare services
Publications
History of USPTO decisions and trademark events.
30 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/21/2024
FIMP
FINAL DISPOSITION PROCESSED
11/21/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/11/2024
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
09/03/2024
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
06/16/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/11/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
06/11/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
06/07/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/26/2024
PUBO
PUBLISHED FOR OPPOSITION
03/26/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/06/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/06/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/17/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
02/17/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/17/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
02/17/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/17/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/23/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/22/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/22/2024
RFNT
REFUSAL PROCESSED BY IB
08/15/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/21/2023
RFRR
REFUSAL PROCESSED BY MPU
07/21/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/15/2023
CNRT
NON-FINAL ACTION WRITTEN
06/14/2023
DOCK
ASSIGNED TO EXAMINER
06/07/2023
MAFR
APPLICATION FILING RECEIPT MAILED
01/13/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/09/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/06/2023
Continuous trademark protection
Get notified about every new filing that threatens DRUGOME or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.